Hoskins, Paul J <br/><br/>
Time for a level playing field: inequalities in regulatory/approval processes—the example of bevacizumab in epithelial ovarian cancer.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  May 2015 
 - 1539-42 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2014.58.3690  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal, Humanized--economics<br/>Antineoplastic Agents--economics<br/>Bevacizumab<br/>Breast Neoplasms--drug therapy<br/>Canada<br/>Carcinoma, Ovarian Epithelial<br/>Clinical Trials as Topic<br/>Colorectal Neoplasms--drug therapy<br/>Cost-Benefit Analysis<br/>Disease-Free Survival<br/>Drug Approval<br/>Drug Costs<br/>European Union<br/>Evidence-Based Medicine<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Neoplasms, Glandular and Epithelial--drug therapy<br/>Ovarian Neoplasms--drug therapy<br/>Politics<br/>Recurrence<br/>Survival Analysis<br/>Treatment Outcome<br/>United Kingdom<br/>United States<br/>United States Food and Drug Administration<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors